Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP869365.RAwvJfTti5asFwI7nvJZBNOzVcELR6zOyTl8CD_jOV1a4130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP869365.RAwvJfTti5asFwI7nvJZBNOzVcELR6zOyTl8CD_jOV1a4130_assertion type Assertion NP869365.RAwvJfTti5asFwI7nvJZBNOzVcELR6zOyTl8CD_jOV1a4130_head.
- NP869365.RAwvJfTti5asFwI7nvJZBNOzVcELR6zOyTl8CD_jOV1a4130_assertion description "[In this report, we focused on roles of expression silencing of ILK in multi-drug resistance reversal of human gastric carcinoma SGC7901/DDP cells, including increased drug sensitivity to cisplatin, cell apoptosis rates, and intracellular accumulation of Rhodamine-123, and decreased mRNA and protein expression of multi-drug resistance gene (MDR1), multi-drug resistance- associated protein (MRP1), excision repair cross-complementing gene 1 (ERCC1), glutathione S-transferase -? (GST-?) and RhoE, and transcriptional activation of AP-1 and NF-?B in ILK silenced SGC7901/DDP cells.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP869365.RAwvJfTti5asFwI7nvJZBNOzVcELR6zOyTl8CD_jOV1a4130_provenance.
- NP869365.RAwvJfTti5asFwI7nvJZBNOzVcELR6zOyTl8CD_jOV1a4130_assertion evidence source_evidence_literature NP869365.RAwvJfTti5asFwI7nvJZBNOzVcELR6zOyTl8CD_jOV1a4130_provenance.
- NP869365.RAwvJfTti5asFwI7nvJZBNOzVcELR6zOyTl8CD_jOV1a4130_assertion SIO_000772 23317227 NP869365.RAwvJfTti5asFwI7nvJZBNOzVcELR6zOyTl8CD_jOV1a4130_provenance.
- NP869365.RAwvJfTti5asFwI7nvJZBNOzVcELR6zOyTl8CD_jOV1a4130_assertion wasDerivedFrom befree-20150227 NP869365.RAwvJfTti5asFwI7nvJZBNOzVcELR6zOyTl8CD_jOV1a4130_provenance.
- NP869365.RAwvJfTti5asFwI7nvJZBNOzVcELR6zOyTl8CD_jOV1a4130_assertion wasGeneratedBy ECO_0000203 NP869365.RAwvJfTti5asFwI7nvJZBNOzVcELR6zOyTl8CD_jOV1a4130_provenance.